Selected highlights from ACTRIMS/ECTRIMS 2020 (posted on September 24, 2020)
Virtual Congress – 11-13 September 2020
50 slides
Scientific review:
Dr. Daniel Selchen, Senior Consultant, Division of Neurology, St. Michael’s Hospital, Toronto, Canada
French version: Translated by Dr. François Émond, Quebec City MS Clinic, Clinical professor, Université Laval, Quebec City, Canada Read More
There has been considerable uncertainty and confusion about the diagnosis of secondary-progressive multiple sclerosis (SPMS), which may stem in part from the MS Phenotype Group’s early efforts to define the clinical course of MS (Lublin et al. Neurology 2014; 83:278-286). In that paper, four sub-phenotypes of SPMS were described: those with active disease with disability progression (once considered to be transitional SPMS); active disease without disability progression (once considered RRMS); non-active disease with progression (once considered SPMS); and non-active disease without progression.
September 13 Edition
September 12 Edition
September 11 Edition
ACTRIMS/ECTRIMS 2020 concluded on September 26th with a special session on COVID-19. Presentations and posters attempted to clarify risk factors for COVID-19 in MS patients, and to address the question of whether disease-modifying therapies (DMT) – most specifically anti-CD20 therapies – affect the risk of acquiring SARS-CoV-2 infection or clinical outcomes of COVID-19. Data were provided by large multinational patient registries and individual MS centres.
8th Joint Americas Committee and European Committee for Treatment and Research in MS (ACTRIMS-ECTRIMS) meeting, Virtual Congress, 11-13 September 2020.
The following summarizes some of the highlights from Day 3 of ACTRIMS-ECTRIMS 2020.
September 26 Edition (special session on COVID-19)
September 12 Edition
September 11 Edition